Monistat-Derm
Brand names,
Monistat-Derm
Analogs
Monistat-Derm
Brand Names Mixture
Monistat-Derm
Chemical_Formula
C27H34N2O7
Monistat-Derm
RX_link
http://www.rxlist.com/cgi/generic2/moexip.htm
Monistat-Derm
fda sheet
Monistat-Derm
msds (material safety sheet)
Monistat-Derm
Synthesis Reference
No information avaliable
Monistat-Derm
Molecular Weight
498.568 g/mol
Monistat-Derm
Melting Point
No information avaliable
Monistat-Derm
H2O Solubility
Soluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.
Monistat-Derm
State
Solid
Monistat-Derm
LogP
3.31
Monistat-Derm
Dosage Forms
Tablets (scored, coated, containing 7.5 mg or 15 mg of moexipril hydrochloride for oral administration)
Monistat-Derm
Indication
For treatment of patients with hypertension.
Monistat-Derm
Pharmacology
Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Monistat-Derm
Absorption
Moexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces Cmax and AUC by about 70% and 40% respectively after the ingestion of a low-fat breakfast or by 80% and 50% respectively after the ingestion of a high-fat breakfast.
Monistat-Derm
side effects and Toxicity
Human overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg.
Monistat-Derm
Patient Information
Monistat-Derm
Organisms Affected
Humans and other mammals